Market Overview

Sangamo Presents Positive Clinical Data from SB-728-T HIV Study


Sangamo BioSciences (NASDAQ: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS.  The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects on long-term anti-retroviral therapy (ART), despite a median duration of HIV infection of 21 years and baseline CD4 T-cell counts prior to SB-728-T treatment of <500 cells/µl. The data were presented  at a translational medicine meeting organized by The Lancet and Cell publications and entitled, "What Will it Take to Achieve an AIDS-Free World?" which is being held in San Francisco, November 3-5, 2013.


"These data are very promising and demonstrate the important link between SB-728-T treatment and immune reconstitution of central memory and total CD4 T cells and lower HIV DNA levels in subjects at 12 months," said Rafick-Pierre Sekaly, Ph.D., Co-Director & Chief Scientific Officer, The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), who presented the data and whose laboratory carried out the immunologic analyses.

ART successfully suppresses viral load in most subjects, but a significant

See full press release

Posted-In: News Guidance Offerings Contracts FDA Management Global


Related Articles (SGMO)

View Comments and Join the Discussion!

Get Benzinga's Newsletters